Recursion Pharmaceuticals (RXRX) Equity Average (2020 - 2026)

Recursion Pharmaceuticals has reported Equity Average for 7 years, with the latest figure at $1.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 9.49% year-over-year to $1.1 billion; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (up 9.49% YoY), and the FY2025 full-year result was $1.1 billion, up 44.55% from the prior year.
• Equity Average for Q1 2026 stood at $1.1 billion, down from $1.1 billion in the prior quarter.
• The five-year high for Equity Average was $1.1 billion in Q4 2025, with the low at $412.8 million in Q3 2022.
• Historically, Equity Average has averaged $645.0 million across 5 years, with a median of $492.8 million in 2024.
• The largest YoY upside for Equity Average was 335.93% in 2022 against a maximum downside of 33.51% in 2022.
• Recursion Pharmaceuticals' Equity Average stood at $436.9 million in 2022, then climbed by 3.15% to $450.7 million in 2023, then surged by 72.99% to $779.7 million in 2024, then soared by 39.66% to $1.1 billion in 2025, then retreated by 1.02% to $1.1 billion in 2026.
• The last three Equity Average figures came in at $1.1 billion (Q1 2026), $1.1 billion (Q4 2025), and $983.0 million (Q3 2025), per Business Quant data.